ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up

• DOI: 10.1007/s13402-013-0125-9
• Publication Date: 2013-02-19T06:09:22Z
• Authors: Agnieszka Halon; Piotr Donizy; Pawel Surowiak; Rafal Matkowski
• Keywords: Medicine(all); rho GTP-Binding Proteins; 0301 basic medicine; Original Paper; Receptors, Steroid; Receptor, ErbB-2; Carcinoma, Ductal, Breast; Microfilament Proteins; Breast Neoplasms; Kaplan-Meier Estimate; Middle Aged; Immunohistochemistry; Cell Compartmentation; 3. Good health; Cytoskeletal Proteins; 03 medical and health sciences; Humans; Female; Stromal Cells; cdc42 GTP-Binding Protein; rhoA GTP-Binding Protein; rhoB GTP-Binding Protein; Follow-Up Studies

The aim of this study was to examine the expression ERM (ezrin, moesin) and Rho (RhoA, RhoB Cdc42) proteins in breast cancer (BC) patients investigate relationship between sub-cellular localisation these clinicopathological characteristics patient survival. specific distribution ERM/Rho analysed by immunohistochemistry a homogeneous group 85 stage II ductal BC with follow-up 15 years. Enhanced immunoreactivity all found be associated presence lymph node metastases P = 0.047, moesin, 0.038, RhoA, 0.024, RhoB, 0.004 Cdc42, 0.047). Nuclear ezrin correlate nodes (P 0.004) histological de-differentiation 0.015). In contrast, we that nuclear topography RhoA perinuclear were strongly lack nodal 0.008, 0.048, 0.001, respectively), whereas decreased reactivity stromal compartment tumours 0.011). No observed protein oestrogen receptor (ER), progesterone (PgR) or HER-2 cells. Also, did not predict survival, but over-expression better prognosis 0.0106). immunoprofile assessment its may instrumental for prediction patients.